BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21859832)

  • 1. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival.
    Slattery ML; Lundgreen A; Bondurant KL; Wolff RK
    Carcinogenesis; 2011 Nov; 32(11):1660-7. PubMed ID: 21859832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case-control study.
    Minami Y; Tateno H
    Cancer Sci; 2003 Jun; 94(6):540-7. PubMed ID: 14529588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation in the transforming growth factor-β-signaling pathway, lifestyle factors, and risk of colon or rectal cancer.
    Slattery ML; Lundgreen A; Wolff RK; Herrick JS; Caan BJ
    Dis Colon Rectum; 2012 May; 55(5):532-40. PubMed ID: 22513431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL6 genotypes and colon and rectal cancer.
    Slattery ML; Wolff RK; Herrick JS; Caan BJ; Potter JD
    Cancer Causes Control; 2007 Dec; 18(10):1095-105. PubMed ID: 17694420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT's role in colorectal carcinogenesis.
    Pellatt AJ; Wolff RK; Herrick J; Lundgreen A; Slattery ML
    Mol Carcinog; 2013 Jul; 52(7):507-13. PubMed ID: 22351525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nongenetic Determinants of Risk for Early-Onset Colorectal Cancer.
    Archambault AN; Lin Y; Jeon J; Harrison TA; Bishop DT; Brenner H; Casey G; Chan AT; Chang-Claude J; Figueiredo JC; Gallinger S; Gruber SB; Gunter MJ; Hoffmeister M; Jenkins MA; Keku TO; Marchand LL; Li L; Moreno V; Newcomb PA; Pai R; Parfrey PS; Rennert G; Sakoda LC; Sandler RS; Slattery ML; Song M; Win AK; Woods MO; Murphy N; Campbell PT; Su YR; Zeleniuch-Jacquotte A; Liang PS; Du M; Hsu L; Peters U; Hayes RB
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34041438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of plasma polyphenol levels and colon cancer risk.
    Murphy N; Achaintre D; Zamora-Ros R; Jenab M; Boutron-Ruault MC; Carbonnel F; Savoye I; Kaaks R; Kühn T; Boeing H; Aleksandrova K; Tjønneland A; Kyrø C; Overvad K; Quirós JR; Sánchez MJ; Altzibar JM; María Huerta J; Barricarte A; Khaw KT; Bradbury KE; Perez-Cornago A; Trichopoulou A; Karakatsani A; Peppa E; Palli D; Grioni S; Tumino R; Sacerdote C; Panico S; Bueno-de-Mesquita HBA; Peeters PH; Rutegård M; Johansson I; Freisling H; Noh H; Cross AJ; Vineis P; Tsilidis K; Gunter MJ; Scalbert A
    Int J Cancer; 2018 Oct; 143(7):1620-1631. PubMed ID: 29696648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development.
    Wang L; Wang Y; Song Z; Chu J; Qu X
    J Interferon Cytokine Res; 2015 Apr; 35(4):273-80. PubMed ID: 25383957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon regulatory factor 6 differentially regulates Toll-like receptor 2-dependent chemokine gene expression in epithelial cells.
    Kwa MQ; Nguyen T; Huynh J; Ramnath D; De Nardo D; Lam PY; Reynolds EC; Hamilton JA; Sweet MJ; Scholz GM
    J Biol Chem; 2014 Jul; 289(28):19758-68. PubMed ID: 24872416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An etiologic regulatory mutation in IRF6 with loss- and gain-of-function effects.
    Fakhouri WD; Rahimov F; Attanasio C; Kouwenhoven EN; Ferreira De Lima RL; Felix TM; Nitschke L; Huver D; Barrons J; Kousa YA; Leslie E; Pennacchio LA; Van Bokhoven H; Visel A; Zhou H; Murray JC; Schutte BC
    Hum Mol Genet; 2014 May; 23(10):2711-20. PubMed ID: 24442519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel heterozygous mutation (F252Y) in exon 7 of the IRF6 gene is associated with oral squamous cell carcinomas.
    Melath A; Santhakumar GK; Madhavannair SS; Nedumgottil BM; Ramanathan A
    Asian Pac J Cancer Prev; 2013; 14(11):6803-6. PubMed ID: 24377609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes.
    Restivo G; Nguyen BC; Dziunycz P; Ristorcelli E; Ryan RJ; Özuysal ÖY; Di Piazza M; Radtke F; Dixon MJ; Hofbauer GF; Lefort K; Dotto GP
    EMBO J; 2011 Nov; 30(22):4571-85. PubMed ID: 21909072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression.
    Tecalco-Cruz AC; Medina-Abreu KH; Oropeza-Martínez E; Zepeda-Cervantes J; Vázquez-Macías A; Macías-Silva M
    World J Clin Oncol; 2024 Feb; 15(2):195-207. PubMed ID: 38455133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and Cancer Survival: An Analysis of Molecular Mechanisms.
    Pandey M; Rajput M; Singh P; Shukla M; Zhu B; Koshiol J
    Cancers (Basel); 2024 Jan; 16(1):. PubMed ID: 38201650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD11c
    Tse BCY; Bergamin S; Steffen P; Hruby G; Pavlakis N; Clarke SJ; Evans J; Engel A; Kneebone A; Molloy MP
    Oncoimmunology; 2023; 12(1):2238506. PubMed ID: 37485033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the relationship between interferon-gamma receptor 1-56C/T gene polymorphism and genetic susceptibility to lung sarcoidosis: A cross-sectional study.
    Kaymaz S; Kavas M; Demiray A; Karasu U; Çobankara V; Boğa S
    Arch Rheumatol; 2023 Mar; 38(1):1-8. PubMed ID: 37235124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy.
    Andreu-Sanz D; Kobold S
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
    Chung BS; Liao IC; Lin PC; Wu SY; Kang JW; Lin BW; Chen PC; Chan RH; Lee CT; Shen MR; Chen SH; Yeh YM
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gamble between oncolytic virus therapy and IFN.
    Li Q; Tan F; Wang Y; Liu X; Kong X; Meng J; Yang L; Cen S
    Front Immunol; 2022; 13():971674. PubMed ID: 36090998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.